Oncologist. The. Promising New Drugs and Combinations

Size: px
Start display at page:

Download "Oncologist. The. Promising New Drugs and Combinations"

Transcription

1 The Oncologist Promising New Drugs and Combinations Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma SANJIV S. AGARWALA, JOHN M. KIRKWOOD ABSTRACT University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA Key Words. Antineoplastic agents Alkylating Central nervous system Drug therapy Imidazoles Melanoma Neoplasm metastasis Pharmacokinetics Temozolomide (TMZ) is the first new chemotherapy agent to be approved for the treatment of high-grade malignant gliomas in more than 20 years. This novel oral alkylating agent has demonstrated promising activity not only in brain tumors, but in a variety of solid tumors, including malignant melanoma. TMZ is 100% bioavailable when taken orally and, because of its small size and lipophilic properties, it is able to cross the blood-brain barrier. Concentrations in the central nervous system are approximately 30% of plasma concentrations. Once it has entered the central nervous system, TMZ can be spontaneously converted to the active metabolite. These pharmacologic properties make it an INTRODUCTION Temozolomide (TMZ; Temodar [Temodal in the United Kingdom and Europe], Schering-Plough Corporation; Kenilworth, NJ) is a novel oral alkylating agent that has demonstrated efficacy in the treatment of a variety of solid tumors, including primary malignant brain tumors and metastatic melanoma [1-7]. TMZ has certain advantages over many existing alkylating agents because of its unique chemical structure and pharmacokinetic properties [8, 9]. Because of its small molecular weight, TMZ efficiently crosses the bloodbrain barrier [10]. Thus, TMZ is effective against primary brain tumors and, for this reason, TMZ is also being actively investigated for the treatment of secondary central nervous ideal agent for treating central nervous system malignancies. In patients with advanced metastatic melanoma, brain metastases are a major cause of treatment failure. In this setting, TMZ has been shown to be as effective as dacarbazine, with a similar safety profile. More importantly, there is evidence to suggest that TMZ-treated patients have a lower incidence of central nervous system relapse compared with dacarbazinetreated patients. Therefore, TMZ is actively being investigated for the treatment and prevention of brain metastases in melanoma patients. TMZ may become an important part of treatment regimens for advanced metastatic melanoma. The Oncologist 2000;5: system (CNS) malignancies, particularly in patients with metastatic melanoma. In addition, TMZ can be administered orally without dietary restrictions, and essentially 100% of the orally administered dose enters the blood stream. TMZ is also associated with a low incidence of severe adverse events. Unlike nitrosoureas and other alkylating agents that chemically cross-link the DNA and are associated with severe, doselimiting, cumulative hematologic toxicity, TMZ is associated with generally mild, noncumulative myelosuppression. TMZ has been extensively investigated for the treatment of high-grade gliomas, including anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), and for the treatment of metastatic melanoma. Based on the results of a phase Correspondence: Sanjiv S. Agarwala, M.D., Associate Director, Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA. Telephone: ; Fax: ; Received January 25, 2000; accepted for publication March 14, AlphaMed Press /00/$5.00/0 The Oncologist 2000;5:

2 Agarwala, Kirkwood 145 II trial in patients with recurrent AA [4], the United States Food and Drug Administration (FDA) recently granted TMZ accelerated approval for the treatment of refractory AA in adult patients at first relapse with disease progression on a nitrosourea and procarbazine-containing regimen. A phase IV trial is under way to confirm the efficacy of TMZ in patients with refractory AA. TMZ has not yet been approved in the United States for the treatment of GBM, because the Oncologic Drugs Advisory Committee (ODAC) did not accept six-month progression-free survival as an adequate clinical end point in the pivotal trial. However, TMZ is currently licensed in Europe for the treatment of any refractory high-grade glioma. Studies are also currently ongoing to demonstrate the efficacy of TMZ as first-line chemotherapy in patients with newly diagnosed high-grade gliomas. Despite a number of studies demonstrating activity, TMZ has not been granted approval in the United States or Europe for the treatment of metastatic melanoma. These studies include a randomized, phase III trial [11] demonstrating that TMZ is at least as active as dacarbazine (DTIC), which is the only chemotherapy agent currently licensed by the FDA for the treatment of melanoma. The ODAC indicated that demonstrating equivalence to DTIC was not sufficient to recommend approval in the United States. TMZ has been approved in Australia for use in metastatic melanoma. The major potential advantage of TMZ over DTIC is that TMZ is able to penetrate the CNS and may be effective against CNS metastases. Although both drugs are converted to the same active compound (i.e., 5-(3-dimethyl-1-triazenyl) imidazole- 4-carboxamide [MTIC]), DTIC is only metabolized in the liver, whereas TMZ is able to cross into the CNS, where it is spontaneously hydrolyzed to the active metabolite. This review will summarize the clinical pharmacology of TMZ, review the data in recurrent glioma, and discuss the potential of TMZ in the treatment of advanced metastatic melanoma. CHEMICAL STRUCTURE AND MECHANISM OF ACTION TMZ belongs to a new class of alkylating agents known as imidazotetrazines. These compounds contain an imidazole ring and are structurally and functionally similar to DTIC, which is a member of the triazene subgroup [9]. TMZ was first synthesized by Stevens and coworkers in 1984 [8], and they were the first to demonstrate that TMZ has anticancer activity [8, 12]. TMZ is a small molecule with a molecular weight of 194 daltons and is, therefore, readily absorbed in the digestive tract and, because it is lipophilic, it is able to cross the blood-brain barrier. TMZ is robustly stable at the acidic ph of the stomach. However, once in contact with the slightly basic ph of the blood and tissues, TMZ spontaneously undergoes hydrolysis to the active metabolite MTIC, which rapidly breaks down to form the reactive methyldiazonium ion (Fig. 1) [9]. Penetration of TMZ into the CNS has been studied in rats and rhesus monkeys, and these studies have shown that the levels of drug in the brain and cerebrospinal fluid are approximately 30% to 40% of the plasma concentration [10]. The metabolite MTIC, however, does not effectively penetrate the CNS. The methyldiazonium ion formed by the breakdown of MTIC primarily methylates guanine residues in the DNA molecule, resulting in the formation of O 6 - and N 7 -methylguanine. The formation of O 6 -methylguanine is primarily responsible for the cytotoxic effects of TMZ and DTIC. When DNA mismatch repair enzymes attempt to excise O 6 -methylguanine, they generate single- and double-strand breaks in the DNA, leading to activation of apoptotic pathways. N 7 -methylguanine is comparatively less cytotoxic because the nucleotide excision repair pathway can successfully excise these adducts without damaging the DNA. TMZ does not result in chemical cross-linking of the DNA strands. Thus, it is less toxic to the hematopoietic progenitor cells in the bone marrow than are the nitrosoureas (i.e., carmustine, lomustine), platinum compounds, and procarbazine, which do cross-link the DNA. CLINICAL PHARMACOLOGY TMZ is rapidly absorbed after oral administration, and the bioavailability is approximately 100%. The absorption of TMZ is only minimally affected by food. Absorption is reduced by only approximately 9% when taken with food, and this is not a clinically significant effect [13]. However, to reduce potential for nausea and vomiting, it is recommended that patients take TMZ at least 1 h before a meal or, preferably, at bedtime. Phase I and II clinical studies have determined the maximum tolerated dose to be 1,000 mg/m 2 divided over five days in each 28-day cycle [1-6]. TMZ is generally well tolerated at these dose levels. The most common nonhematologic adverse events are nausea, vomiting, headache, fatigue, and constipation. These events are generally mild to moderate in severity, and nausea and vomiting are readily controlled with standard antiemetics. With regard to hematologic toxicities, the incidence of grade 3/4 neutropenia and thrombocytopenia is generally lower than 10%, and fewer than 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression. Myelosuppression is generally not cumulative and seldom results in discontinuation of treatment. Based on the favorable toxicity profile observed in early clinical trials, subsequent studies have investigated doses of 150 mg/m 2 /day 5 days for patients who had previously been treated with cytotoxic chemotherapy (total dose = 750 mg/m 2 per cycle), with a planned increase to

3 146 Temozolomide May Improve Treatment of Advanced Melanoma Figure 1. Metabolism of temozolomide in aqueous solution. Reprinted with permission [9]. 200 mg/m 2 /day if no major myelosuppression was evident on day 22 of the 28-day cycle. For previously untreated patients, the initial dose is typically 200 mg/m 2 /day 5 days (total dose = 1,000 mg/m 2 per cycle). A continuous oral dosing schedule has also been investigated in a phase I trial [14]. Administration of 75 mg/m 2 /day for six to seven weeks was well tolerated and resulted in a twofold increase in drug exposure over four weeks compared with the fiveday every 28 days schedule. This regimen produced a 33% objective response rate among 24 patients with varying tumor types, including 17 patients with gliomas. The continuous daily regimen lends itself to potential combination with fractionated radiation therapy. The pharmacokinetics of TMZ after administration at 150 and 200 mg/m 2 on a five-day schedule have been evaluated in humans (Table 1) [15]. The data indicate that TMZ is rapidly absorbed and eliminated. The mean time to maximal plasma concentration was less than 1 h, and the mean terminal elimination half-life was approximately 1.8 h. The maximum plasma concentration was 7.75 and 10.7 µg/ml at the 150 and 200 mg/m 2 doses, respectively. Figure 2 [16] shows the plasma concentration curve after oral administration of a Table 1. Single-dose pharmacokinetics of temozolomide Oral dose 150 mg/m mg/m 2 Parameter (n = 12) (n = 6) C max 7.75 µg/ml 10.7 µg/ml T max 0.85 h 0.89 h AUC infinity 22.6 µg h/ml 29.7 µg h/ml T 1/ h 1.84 h Clearance 3.05 ml/kg/min 2.85 ml/kg/min Volume of distribution 0.48 l/kg 0.45 l/kg C max = maximum plasma concentration; T max = time of maximal concentration; AUC = area under the curve; T 1/2 = terminal elimination half-life. From data on file [15]. Figure 2. Plasma concentration versus time curve after oral administration of a single dose of temozolomide (TMZ). From data on file [16].

4 Agarwala, Kirkwood 147 single dose of TMZ ranging from 100 to 250 mg/m 2. Nearly all of the administered dose was eliminated within 8 h. Because of its rapid elimination and its mechanism of action, TMZ has a reduced risk of causing cumulative hematologic toxicity. The mean plasma area under the curve of TMZ after oral administration was 22.6 and 29.7 µg h/ml after a dose of 150 and 200 mg/m 2, respectively. These pharmacokinetic characteristics have been evaluated in a number of clinical studies and are consistent among studies and in different patient subgroups, including pediatric patients [5, 17-20]. CELLULAR RESISTANCE MECHANISMS Several cellular mechanisms of resistance to alkylating agents have been identified. These include defects in DNA mismatch repair, increased excision repair, and increased enzymatic removal of alkyl groups. One of the key enzymes responsible for removing methyl groups from O 6 -methylguanine is O 6 -alkylguanine transferase (AGT), also known as O 6 - methylguanine methyltransferase. Overexpression of AGT can lead to resistance to the cytotoxic effects of MTIC. However, TMZ is able to deplete the levels of AGT in various cell types, thus reducing the potential for drug resistance [21-23]. A potential advantage of continuous low-dose administration of TMZ may be the more sustained depletion of AGT that can be achieved using this schedule. Two studies have investigated the relationship between cellular AGT levels and response to TMZ and have yielded disparate results [7, 24]. Middleton et al. [7] reported that among 33 melanoma patients in whom pretreatment AGT level and clinical response could be correlated, the AGT level was not predictive of response to TMZ. In contrast, Friedman et al. [24] reported that among newly diagnosed patients with high-grade gliomas, those patients with fewer than 20% AGT-staining cells had a substantially higher response rate compared with patients with greater than 20% AGT-positive cells (76% versus 27%). Among 25 patients with fewer than 20% AGT-positive cells, there were three patients with a complete response, 12 patients with a partial response, and four patients with stable disease. This is compared with only one partial response and two patients with stable disease among 11 patients with greater than 20% AGT-positive cells. This study suggests that lower expression of AGT correlates with improved response to TMZ. PIVOTAL DATA IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TMZ has demonstrated activity in patients with recurrent AA and GBM. The pivotal phase II trial in patients with recurrent AA enrolled 162 patients at 15 United States sites and 17 international sites [25]. Eligible patients had histologically confirmed AA or anaplastic oligoastrocytoma and had failed initial therapy, which could have included surgery, radiation therapy, and chemotherapy. Patients could have received only one prior chemotherapy regimen that included a nitrosourea. Eligible patients were required to have a good Karnofsky performance status (i.e., 70) and a life expectancy of at least 12 weeks. All patients received TMZ at a dose of 150 to 200 mg/m 2 /day 5 days every 28 days until disease progression, for a maximum of two years. This is the largest trial ever conducted in this patient population, and it was well designed with rigorously defined prospective criteria for determining response and progression using gadolinium-enhanced magnetic resonance imaging. The patient s neurologic status and corticosteroid use were also considered by the investigators when determining response and progression, and responses were confirmed by central neuroradiology review of the magnetic resonance imaging scans. The primary clinical end points were six-month progression-free survival (PFS), overall survival, and response rate. In this trial, TMZ produced a six-month PFS rate of 46% in the intent-to-treat population. The six-month overall survival rate was 75%, with a median overall survival of 13.6 months (Table 2) [4]. This compares very favorably with published studies; expected median survival for patients with recurrent AA is only six to nine months [26-31]. The number of responding patients in this trial was also very encouraging. The 62% overall response rate is superior to most response rates reported in the literature [26], and a substantial number (8%) of patients achieved a complete response. Within the total patient population in this trial, 54 patients were deemed to have refractory disease, having failed treatment with Table 2. Efficacy summary in patients with anaplastic glioma Efficacy Intent-to-treat Refractory patients parameter (n = 162) (n = 54) Progression-free survival 6-month rate 46% 45% 12-month rate 24% 29% Median 5.4 months 4.4 months Overall survival 6-month rate 75% 74% 12-month rate 56% 65% Median 13.6 months 15.9 months Response rate * Complete 8% 9% Objective (CR + PR) 35% 22% Overall (CR + PR + SD) 62% 59% AA = anaplastic astrocytoma; AOA = anaplastic oligoastrocytoma; NR = not reported; CR = complete response; PR = partial response; SD = stable disease. * All responses were centrally reviewed.

5 148 Temozolomide May Improve Treatment of Advanced Melanoma procarbazine, vincristine, and lomustine (PCV regimen), which is the standard first-line therapy for AA. Within this subgroup the six-month PFS rate was 45%, the six-month overall survival rate was 74% with a median of 15.9 months, and 59% of patients responded to TMZ (Table 2). TMZ was well tolerated in this trial. Nausea, vomiting, headache, fatigue, and constipation were the most commonly reported adverse events. The majority of nonhematologic adverse events were mild to moderate in severity (World Health Organization [WHO] grade 1 or 2). Only 7% of treated patients developed thrombocytopenia (6% grade 3/4), and only 2% of treated patients developed grade 3/4 neutropenia and leukopenia. Myelosuppression was generally not cumulative and resulted in discontinuation of treatment in only five patients. The majority (93%) of patients received more than one treatment cycle, and 50% of patients received five cycles. Very few dose reductions or treatment delays were required in this trial because of toxicity. Dose reductions occurred in only 4% of cycles, mainly for hematologic toxicity. Treatment delays due to hematologic toxicity occurred in 28% of cycles. Based upon the results of this trial, the FDA approved the use of TMZ in patients with refractory AA in first relapse. A similar, large, well-designed, phase II trial was conducted in patients with recurrent GBM and demonstrated a significant improvement in six-month PFS compared with procarbazine [32]. Moreover, this trial demonstrated that TMZ was well tolerated, prolonged the time to clinical worsening, and was associated with improved quality of life compared with procarbazine. Both of these trials in patients with recurrent high-grade gliomas demonstrated that TMZ is active and produces response rates comparable to other currently available chemotherapy agents. Therefore, TMZ may provide a meaningful clinical benefit to patients with recurrent high-grade gliomas. TREATMENT OF ADVANCED METASTATIC MELANOMA Patients with advanced (i.e., stage IV) metastatic melanoma also have few available treatment options. The five-year survival rate for these patients is less than 5%, and median survival is in the range of six to nine months. Current treatment options include systemic single-agent chemotherapy with agents such as DTIC, cisplatin, and nitrosoureas; combination chemotherapy; systemic therapy with biologic agents, particularly interleukin 2 (IL-2); and combinations of chemotherapy and biologic agents (i.e., biochemotherapy). Single-agent chemotherapy produces response rates of approximately 20%, with few, if any, long-term remissions. Historically, DTIC has produced response rates of 15% to 25%, with median response durations of five to six months, but less than 5% of responses are complete [33]. As is the case with most chemotherapy agents, responses are generally not durable. Combination chemotherapy produces higher response rates but no improvement in survival compared with single-agent chemotherapy, despite the added toxicity and cost [34]. Dacarbazine has remained the mainstay of many combination chemotherapy regimens, including the popular Dartmouth regimen, consisting of DTIC, cisplatin, carmustine, and tamoxifen. However, a recent Eastern Cooperative Oncology Group randomized trial has demonstrated that the Dartmouth regimen was not significantly more effective than single-agent DTIC and was associated with significantly greater toxicity [34]. Therefore, despite more than 20 years of research, DTIC remains the standard against which all new chemotherapy agents are compared. Single-agent, high-dose IL-2 produces sustained remission in a small subset of patients (5% to 10%) [35], but toxicity is considerable. Biochemotherapy is a promising approach with encouraging results in phase II studies [36-39], but a survival benefit has not been confirmed by ongoing randomized trials [40, 41]. The failure of current biochemotherapy regimens, which can produce objective tumor responses in upwards of 50% of treated patients, is often a result of CNS relapse. Several patients apparently cured by high-dose IL-2 therapy have suffered isolated CNS relapse [35]. The majority of patients with advanced metastatic disease will eventually die of either respiratory failure or brain metastases. Therefore, any agent that can effectively penetrate the CNS with activity in melanoma could provide a major advance in the treatment of this disease. TMZ appears to be a candidate for just such an agent. It has demonstrated activity against melanoma and is able to penetrate the CNS; therefore, TMZ could be an exciting new alternative to DTIC, which is ineffective against CNS metastases. The activity of TMZ in metastatic melanoma was first established in several phase I/II studies conducted by the Cancer Research Campaign [5-7]. Subsequently a large, multicenter, randomized, phase III, pivotal trial was conducted by European investigators to prospectively compare the efficacy of TMZ with that of DTIC [11]. This trial enrolled 305 patients with advanced metastatic melanoma who were randomized to receive oral TMZ (200 mg/m 2 5 days, every 28 days) or intravenous DTIC (250 mg/m 2 5 days, every 21 days). Eligible patients were older than 18 years of age and were previously untreated for metastatic disease. Patients with brain metastases were excluded. The primary efficacy end point was overall survival, and secondary end points included PFS, response rate, and quality of life. Patients were stratified before randomization based on important prognostic factors, including gender, WHO performance status, and site(s) of metastatic disease. Treatment groups were well balanced with respect to age, WHO performance

6 Agarwala, Kirkwood 149 status, sites of metastases, and time from initial diagnosis to diagnosis of metastatic disease. Of note, the proportion of patients with liver metastases was equal between treatment groups (33% in the TMZ arm versus 34% in the DTIC arm). As shown in Table 3 [42], TMZ compared favorably with DTIC in this trial. Response rates were similar, and TMZ demonstrated a slight but not statistically significant progression-free and overall survival advantage. These results suggest that TMZ is at least as effective as DTIC in this patient population. The toxicity profiles of the two drugs were also nearly identical. Both treatments were well tolerated. The most common adverse events were nausea (52%), vomiting (34%), pain (34%), constipation (30%), headache (22%), and fatigue (20%). Most of these adverse events were mild to moderate (WHO grade 1 to 2) and manageable. Thrombocytopenia occurred in 9% of patients in both groups, and grade 3/4 thrombocytopenia occurred in 7% of TMZ-treated patients and in 8% of DTIC-treated patients. Myelosuppression resulted in discontinuation in 3% of TMZ-treated patients compared with 5% of DTICtreated patients. Of interest was that TMZ demonstrated an advantage in terms of improved quality of life. At week 24, a larger proportion (86% versus 38%) of patients in the TMZ arm had maintained or improved scores for physical functioning and global quality of life (77% versus 38%) compared with the DTIC arm. Table 3. Efficacy summary in patients with advanced metastatic melanoma Efficacy Temozolomide DTIC parameter (n = 156) (n = 149) Response rate Complete 3% 3% Partial 11% 9% Objective (CR + PR) 13% 12% Progression-free survival 6-month rate 12% 5% Median Overall survival 6-month rate 61% 51% (ITT analysis) 12-month rate 33% 27% (ITT analysis) Median 7.7 months 6.4 months (ITT analysis) Median (treated 7.9 months 5.7 months eligible population) (n = 144) (n = 136) CR = complete response; PR = partial response; ITT = intent-to-treat. From data on file [42]. TREATMENT AND PREVENTION OF BRAIN METASTASES Although the phase III trial described above did not evaluate the efficacy of TMZ in patients with brain metastases, this remains an important question and one that is currently being addressed. Based on the clinical pharmacology of TMZ, it has been suggested that TMZ may be effective in the prevention and treatment of brain metastases. The levels of TMZ in the cerebrospinal fluid have been evaluated in a single melanoma patient following administration of TMZ at a dose of 150 mg/m 2 /day for five consecutive days. This study showed that the mean concentration of TMZ in the cerebrospinal fluid was approximately 30% of the plasma concentration on day 1 and day 5 [43]. These findings are consistent with previously published preclinical studies [10]. Therefore, TMZ would be expected to be more effective than DTIC in patients with brain metastases and may have a role in the prevention of brain metastases. A recent report of a retrospective case review has provided preliminary support for this supposition. Summers et al. [44] have reported that among 40 patients with advanced melanoma treated with TMZ (n = 19) or DTIC (n = 21), the incidence of CNS relapse was lower in patients treated with TMZ. Two of 19 (10%) patients treated with TMZ developed CNS metastasis compared with 8 of 21 (38%) patients treated with DTIC. A multicenter, international, phase II trial of TMZ in melanoma patients with brain metastases before radiation therapy has also recently been completed and the data will be available soon. FUTURE DIRECTIONS The question remains how to incorporate TMZ into the current treatment strategies for metastatic melanoma. One attractive option is to combine it with other agents that have demonstrated efficacy in this disease. Several combination regimens have been investigated in phase I trials. We have reported a phase I trial of TMZ in combination with interferon alfa-2b in patients with previously untreated metastatic melanoma [45]. The preliminary report of this trial demonstrated that 750 mg/m 2 TMZ over five days plus interferon alfa-2b (5 to 10 million IU/m 2 subcutaneously three times per week) was well tolerated. Dose-limiting hematologic toxicity resulted in dose reductions in only 3 of 43 cycles; reversible hematologic toxicity resulted in dose delays in 18 of 43 cycles. A phase I trial of TMZ in combination with cisplatin has also been reported [46]. The rationale for this combination is based on the demonstrated single-agent activity of each of these drugs in melanoma, as well as the observation that cisplatin can inactivate AGT; subtherapeutic concentrations of cisplatin can increase the sensitivity of leukemic blasts to TMZ [46]. This study established the maximum

7 150 Temozolomide May Improve Treatment of Advanced Melanoma tolerated dose of cisplatin at 75 mg/m 2 on day 1 of each 28- day cycle with TMZ (200 mg/m 2 /day 5 days). Cisplatin did not alter the pharmacokinetics of TMZ or alter its toxicity profile. No efficacy data were reported. These preliminary studies have established that TMZ can be combined with other chemotherapy agents and with biologic agents without increasing toxicity. TMZ is also currently being investigated in a number of phase II biochemotherapy protocols in which TMZ is being substituted for DTIC. The Cytokine Working Group is conducting a phase II study of TMZ in combination with radiation therapy for patients with brain metastases. A trial has also been proposed to investigate whether the low-dose daily regimen of TMZ can prevent CNS relapse in patients who have been definitively treated for melanoma brain metastases with surgical excision or radiosurgery. REFERENCES 1 O Reilly SM, Newlands ES, Glaser MG et al. Temozolomide: a new cytotoxic agent with promising activity against primary brain tumors. Eur J Cancer 1993;29: Newlands ES, O Reilly SM, Glaser MG et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996;32A: Bower M, Newlands ES, Bleehen NM et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive highgrade glioma. Cancer Chemother Pharmacol 1997;40: Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17: Newlands ES, Blackledge GR, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC ). Br J Cancer 1992;65: Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13: Middleton MR, Lunn JM, Morris C et al. O 6 -Methylguanine- DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78: Stevens MF, Hickman JA, Stone R et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2- chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984;27: Newlands ES, Stevens MFG, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23: Patel M, McCully C, Godwin K et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 1995;14:461a. CONCLUSION TMZ has demonstrated efficacy in patients with recurrent high-grade gliomas and appears to be at least equivalent in efficacy to DTIC for the treatment of advanced-stage melanoma, in which it may be effective in the treatment and prevention of brain metastases. TMZ is a convenient, orally bioavailable alkylating agent with excellent tolerability that may be useful as an alternative to DTIC either as a single agent or as part of combination regimens, including biochemotherapy regimens, for the treatment of metastatic melanoma. Its ease and convenience of administration make TMZ an attractive alternative to DTIC for patients with metastatic melanoma in whom palliation is a reasonable goal. Further study of this important new agent is warranted to determine the most effective application in the treatment of metastatic melanoma and other solid tumors. 11 Middleton M, Grob J, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18: Stevens MF, Hickman JA, Langdon SP et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4( 3 H)- one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47: Reidenberg P, Statkevich P, Judson I et al. Effect of food on the oral bioavailability of temozolomide, a new chemotherapeutic agent. Proc Am Soc Clin Pharmacol Ther 1996;59:199a. 14 Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58: Data on File. Kenilworth, NJ: Schering-Plough Corporation, Data on File. Study CI Kenilworth, NJ: Schering- Plough Corporation, Nicholson HS, Ames MM, Krailo M et al. Phase I and pharmacokinetic study of temozolomide (TEM) in children and adolescents. A report from the Children s Cancer Group (CCG). Proc Am Soc Clin Oncol 1995;14:449a. 18 Dhodapkar M, Reid J, Ames MM et al. Phase I clinical trial and pharmacokinetics of temozolamide (NSC ). Proc Am Assoc Cancer Res 1994;35:245a. 19 Eckardt JR, Weiss GR, Burris HA et al. Phase I clinical trial and pharmacokinetic trial of SCH52365 (temozolomide) given orally daily 5 days. Proc Am Soc Clin Oncol 1995;14:484a. 20 Estlin EJ, Lashford L, Ablett S et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children s Cancer Study Group. Br J Cancer 1998;78:

8 Agarwala, Kirkwood Gander M, Leyvraz S, Perey L et al. Association of temozolomide (TMZ) and fotemustine (FOTE) in metastatic melanoma. An approach based on O 5 -alkyl-guanine-dna alkyl transferase depletion (AT). Proc Am Soc Clin Oncol 1994;13:158a. 22 Lee SM, Thatcher N, Crowther D et al. Inactivation of O 6 -alkylguanine-dna alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69: Gerson SL, Sprio TP, Reidenberg P et al. Rapid depletion of O 6 -alkylguanine-dna alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 1996;15:178a. 24 Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O 6 -alkylguanine-dna alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16: Levin V, Yung A, Prados M et al. Phase II study of Temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol 1997;16:384a. 26 Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 1998;18: Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991;9: Jeremic B, Grujicic D, Jevremovic S et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992;10: Buckner J, Brown L, Cascino T et al. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neurooncol 1990;9: Fulton D, Ursasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 1996;27: Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17: Yung A, Levin VA, Albright R et al. Randomized trial of Temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol 1999;18:139a. 33 Balch CM, Reintgen DS, Kirkwood JM et al. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th Ed. Philadelphia: Lippincott-Raven, 1997: Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17: Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and J Clin Oncol 1999;17: Legha S, Ring S, Eton O et al. Durable complete responses (CR s) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-α). Proc Am Soc Clin Oncol 1995;14:412a. 37 Legha SS, Ring S, Bedikian A et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7: Richards JM, Gale D, Mehta N et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999;17: Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa- 2a for metastatic melanoma. J Clin Oncol 1993;11: Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17: Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15: Data on file. I Kenilworth, NJ: Schering-Plough Corporation, Agarwala S, Reyderman L, Statkevich P et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol 1998;9(suppl 4):659a. 44 Summers Y, Middleton M, Calvert H et al. Effect of temozolomide (TMZ) on central nervous system (CNS) relapse in patients with advanced melanoma. Proc Am Soc Clin Oncol 1999;18:531a. 45 Kirkwood JM, Agarwala SS, Diaz B et al. Phase I study of temozolomide in combination with interferon alfa-2b in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1997;16:491a. 46 Britten CD, Rowinsky EK, Baker SD et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 1999;5:

References: Published Clinical Trials in Metastatic Melanoma

References: Published Clinical Trials in Metastatic Melanoma References: Published Clinical Trials in Metastatic Melanoma Melanoma historical data summary While results from open-label, or uncontrolled, or small # center studies can vary enormously, results from

More information

Horizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.

Horizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre. Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the

More information

Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience

Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly

More information

Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review Ian Quirt, Shailendra Verma, Teresa Petrella, Kate Bak and Manya Charette

Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review Ian Quirt, Shailendra Verma, Teresa Petrella, Kate Bak and Manya Charette Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review Ian Quirt, Shailendra Verma, Teresa Petrella, Kate Bak and Manya Charette The Oncologist 2007, 12:1114-1123. doi: 10.1634/theoncologist.12-9-1114

More information

Management of Brain Metastases Sanjiv S. Agarwala, MD

Management of Brain Metastases Sanjiv S. Agarwala, MD Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):

More information

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.

More information

ONCE MELANOMA reaches advanced stages, it is

ONCE MELANOMA reaches advanced stages, it is Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial By Wen-Jen Hwu, Susan E. Krown, Katherine S. Panageas, Jennifer H. Menell, Paul B. Chapman, Philip O. Livingston,

More information

Temozolomide in the treatment of recurrent malignant glioma in Chinese patients!"#$%&'()*+,-./0,1234

Temozolomide in the treatment of recurrent malignant glioma in Chinese patients!#$%&'()*+,-./0,1234 Key words: Astrocytoma; Brain neoplasms; Disease-free survival; Glioblastoma; Neoplasm recurrence!!"!"!"#$ DTM Chan WS Poon YL Chan HK Ng Hong Kong Med J 2005;11:452-6 The Chinese University of Hong Kong,

More information

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional

More information

Clinical Study Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

Clinical Study Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma Hindawi Publishing Corporation Sarcoma Volume 28, Article ID 41253, 7 pages doi:1.1155/28/41253 Clinical Study Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic

More information

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Original article Annals of Oncology 16: 1177 1184, 2005 doi:10.1093/annonc/mdi225 Published online 27 April 2005 Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable

More information

Current and future developments in the use of temozolomide for the treatment of brain tumours

Current and future developments in the use of temozolomide for the treatment of brain tumours Current and future developments in the use of temozolomide for the treatment of brain tumours Roger Stupp, Marc Gander, Serge Leyvraz, and Edward ewlands Brain tumours comprise only 2% of all adult cancers,

More information

HDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine

HDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs

More information

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester

More information

PROCARBAZINE, lomustine, and vincristine (PCV) is

PROCARBAZINE, lomustine, and vincristine (PCV) is RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine

More information

Overall and Progression-Free Survival in Metastatic Melanoma: Analysis of a Single-Institution Database

Overall and Progression-Free Survival in Metastatic Melanoma: Analysis of a Single-Institution Database This review of a single-institution experience in treating metastatic melanoma examines the utility of different treatments and suggests guidelines for interpreting survival and disease-free survival in

More information

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010 University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,

More information

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study 1

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study 1 Neuro-Oncology Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study 1 Michael D. Prados, 2 W.K. Alfred Yung, Howard A. Fine, Harry S.

More information

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012 Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Temozolomide Capsules I.P. Composition TEMOLOZ Each Capsule contains: Temozolomide I.P. 250 mg. TEMOLOZ-100. Each Capsule contains

Temozolomide Capsules I.P. Composition TEMOLOZ Each Capsule contains: Temozolomide I.P. 250 mg. TEMOLOZ-100. Each Capsule contains Temozolomide Capsules I.P. Composition TEMOLOZ -250 Each Capsule contains: Temozolomide I.P. 250 mg. TEMOLOZ-100 Each Capsule contains Temozolomide I.P. 100 mg. TEMOLOZ-20 Each Capsule contains Temozolomide

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer

More information

A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma

A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November

More information

Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity

Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity DEBORAH ARMSTRONG, SEAMUS O REILLY Johns Hopkins Oncology Center, Baltimore, Maryland, USA Key Words. Topotecan Topoisomerase I inhibitor

More information

National Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment

National Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and

More information

Lipoplatin monotherapy for oncologists

Lipoplatin monotherapy for oncologists Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas

More information

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously

More information

Extended-schedule dose-dense temozolomide in refractory gliomas

Extended-schedule dose-dense temozolomide in refractory gliomas J Neurooncol (2010) 96:417 422 DOI 10.1007/s11060-009-9980-7 CLINICAL STUDY - PATIENT STUDY Extended-schedule dose-dense temozolomide in refractory gliomas A. Berrocal Æ P. Perez Segura Æ M. Gil Æ C. Balaña

More information

FACT SHEET. About Optune

FACT SHEET. About Optune About Optune Optune is the Tumor Treating Fields (TTFields) delivery system that is approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with glioblastoma.

More information

Marked inactivation of O 6 -alkylguanine-dna alkyltransferase activity with protracted temozolomide schedules

Marked inactivation of O 6 -alkylguanine-dna alkyltransferase activity with protracted temozolomide schedules British Journal of Cancer (23) 88, 14 111 & 23 Cancer Research UK All rights reserved 7 92/3 $25. www.bjcancer.com Marked inactivation of O 6 -alkylguanine-dna alkyltransferase activity with protracted

More information

SUPPLEMENTARY INFORMATION In format provided by Sebti et al. (NOVEMBER 2011)

SUPPLEMENTARY INFORMATION In format provided by Sebti et al. (NOVEMBER 2011) Supplementary Information S4 Clinical trials with farnesyltransferase inhibitors Drug(s) Disease Phase Patients Median Age Tipifarnib CR Clinical response PR HI SD PD MD FT or Prenylation Response rate

More information

Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date

Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date MP 8.01.03 Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with

More information

Douglas Jolly Executive VP R&D Tocagen Inc.

Douglas Jolly Executive VP R&D Tocagen Inc. REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008 Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study J Neurooncol (2012) 108:195 200 DOI 10.1007/s11060-012-0832-5 CLINICAL STUDY Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study Walter Taal Joyce M. W. Segers-van Rijn

More information

Vision of the Future: Capecitabine

Vision of the Future: Capecitabine Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine

More information

Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study

Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy

More information

It s s Always Something!

It s s Always Something! It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers

More information

Who is the Ideal Candidate for PEG Intron?

Who is the Ideal Candidate for PEG Intron? Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction

More information

AUSTRALIAN PRODUCT INFORMATION TEMODAL (temozolomide) Capsules

AUSTRALIAN PRODUCT INFORMATION TEMODAL (temozolomide) Capsules AUSTRALIAN PRODUCT INFORMATION TEMODAL (temozolomide) Capsules 1 NAME OF THE MEDICINE Temozolomide 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Temozolomide is slightly soluble in water (3.1 mg/ml), methanol

More information

Systemic Therapy of Melanoma Current Approved Options

Systemic Therapy of Melanoma Current Approved Options Systemic Therapy of Melanoma Current Approved Options Stage IIb-III (high risk) Melanoma Only High-dose IFNα is approved by US FDA Stage IV (inoperable) survival

More information

trial update clinical

trial update clinical trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.

More information

PRODUCT INFORMATION. TEMODAL Capsules

PRODUCT INFORMATION. TEMODAL Capsules PRODUCT INFORMATION TEMODAL Capsules NAME OF THE MEDICINE Temozolomide Chemical Name: imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,3,4-dihydro-3-methyl-4-oxo CAS Registry Number: 85622-93-1 Molecular

More information

CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.

CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage

More information

Cancer Registry Report. Cancer Focus: Melanoma

Cancer Registry Report. Cancer Focus: Melanoma Cancer Registry Report Cancer Focus: Melanoma In 2005, nearly 60,000 patients were diagnosed with melanoma, resulting in about 7800 deaths Fortunately, melanoma is often diagnosed in an early stage when

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of

More information

Clinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date:

Clinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date: Clinical Policy: (Temodar) Reference Number: ERX.SPA.138 Effective Date: 03.01.14 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca

More information

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018 VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may

More information

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology

More information

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and

More information

Topotecan: An Oncologist s View

Topotecan: An Oncologist s View Topotecan: An Oncologist s View JEAN-FRANÇOIS HÉRON Centre François Baclesse, Centre Régional de Lutte Contre le Cancer, Caen, France Key Words. Topotecan Clinical trials Ovarian neoplasms Small cell lung

More information

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035. Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller

More information

Concomitant Accelerated Hyper-Fractionated Radiotherapy and Temozolomide in the Treatment of High Grade Astrocytoma

Concomitant Accelerated Hyper-Fractionated Radiotherapy and Temozolomide in the Treatment of High Grade Astrocytoma Journal of the Egyptian Nat. Cancer Inst., Vol. 14, No. 1, March: 9-15, 00 Concomitant Accelerated Hyper-Fractionated Radiotherapy and Temozolomide in the Treatment of High Grade Astrocytoma TAREK HASHEM,M.D.*

More information

Data Sheet. Temozolomide 5mg, 20mg,100mg,140mg,180mg, 250mg Capsules

Data Sheet. Temozolomide 5mg, 20mg,100mg,140mg,180mg, 250mg Capsules Data Sheet TEMACCORD CAPSULES Temozolomide capsules Name of Medicine TEMACCORD CAPSULES Temozolomide 5mg, 20mg,100mg,140mg,180mg, 250mg Capsules Presentation Temaccord capsules are presented in six strengths.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Update: New Treatment Modalities

Update: New Treatment Modalities ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant

More information

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

Special pediatric considerations are noted when applicable, otherwise adult provisions apply. DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM

More information

To assess safety profiles: significant laboratory changes and adverse events (AEs).

To assess safety profiles: significant laboratory changes and adverse events (AEs). These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Chemotherapy in malignant brain tumors

Chemotherapy in malignant brain tumors Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma

More information

PRODUCT INFORMATION Orion Temozolomide Capsules

PRODUCT INFORMATION Orion Temozolomide Capsules PRODUCT INFORMATION Orion Temozolomide Capsules NAME OF THE MEDICINE Temozolomide Temozolomide Chemical Name: imidazo[,-d]-,,,-tetrazine-8-carboxamide,,4-dihydro--methyl-4-oxo CAS Registry Number: 86-9-

More information

Scottish Medicines Consortium

Scottish Medicines Consortium P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib)

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Lynn S. Ashby 1*, Kris A. Smith 2 and Baldassarre Stea 3

Lynn S. Ashby 1*, Kris A. Smith 2 and Baldassarre Stea 3 Ashby et al. World Journal of Surgical Oncology (2016) 14:225 DOI 10.1186/s12957-016-0975-5 REVIEW Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide

More information

Neuro-Oncology Program

Neuro-Oncology Program Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive

More information

Corporate Overview. May 2017 NASDAQ: CYTR

Corporate Overview. May 2017 NASDAQ: CYTR Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY

More information

Citation Cancer Management and Research, 2(1

Citation Cancer Management and Research, 2(1 NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date

More information

Corporate Overview. July 2016 NASDAQ: CYTR

Corporate Overview. July 2016 NASDAQ: CYTR Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE

More information

LUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?

LUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced? LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,

More information

A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)

A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) Morten Mau-Sorensen 1, Scott Plotkin 2, Patrick Wen 3, Andrew

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Adverse side effects associated to metronomic chemotherapy

Adverse side effects associated to metronomic chemotherapy Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there

More information

Lung cancer is the most common cause of cancer-related

Lung cancer is the most common cause of cancer-related GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and

More information

SCH TEMOZOLOMIDE CAPSULES PAGE 1 MODULE PACKAGE INSERT PRODUCT INFORMATION

SCH TEMOZOLOMIDE CAPSULES PAGE 1 MODULE PACKAGE INSERT PRODUCT INFORMATION SCH 52365 TEMOZOLOMIDE CAPSULES PAGE 1 MODULE 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 F XXXXXXXX PRODUCT INFORMATION TEMODAR (temozolomide) CAPSULES DESCRIPTION TEMODAR Capsules for oral administration contain

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and

More information

Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D.

Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South

More information

CILENT P Leblond, DIPG Meeting, Barcelone 2012

CILENT P Leblond, DIPG Meeting, Barcelone 2012 CILENT-0902 Cilengitide (EMD121974) in combination with irradiation in children and adolescents with newly diagnosed diffuse intrinsic brainstem glioma : Phase I Study P Leblond, DIPG Meeting, Barcelone

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

The Center for Cancer Care and Research, St. Louis, Missouri, USA

The Center for Cancer Care and Research, St. Louis, Missouri, USA The Oncologist Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer JOHN R. ECKARDT The Center for Cancer Care and Research, St. Louis, Missouri, USA Key Words. Alternate schedule Recurrent

More information

gp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience

gp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience gp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience Metastatic Melanoma- Progress in Past 30 years Approved Therapies (USA) Date DTIC

More information

Update: Chronic Lymphocytic Leukemia

Update: Chronic Lymphocytic Leukemia ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide 405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD

More information

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Annals of Oncology 12: 259-266. 2001. 2001 Kluwer Academic Publishers. Printed in the Netherlands Original article Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at

More information

Citation Pediatrics international (2015), 57.

Citation Pediatrics international (2015), 57. Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Practice of Interferon Therapy

Practice of Interferon Therapy Interferon Therapy Practice of Interferon Therapy Brain tumor JMAJ 47(1): 18 23, 2004 Toshihiko WAKABAYASHI* and Jun YOSHIDA** *Associate Professor, Center for Genetic and Regenerative Medicine, Nagoya

More information

Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination

Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment

More information

CHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling

CHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling CHK1 Inhibitor Prexasertib, LY2606368 MsOH H 2 O Derived from Garrett MD and Collins I 1 ; Thompson R and Eastman A. 2 Drug Discovery Platform: Cancer Cell Signaling A Phase 2 Study of LY2606368 in Patients

More information

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the

More information

Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)

Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,

More information

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer. Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor

More information

Background. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1

Background. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1 2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson

More information